PT  - JOURNAL ARTICLE
AU  - Álvarez-Mercado, Ana Isabel
AU  - López Plaza, Bricia
AU  - Plaza-Diaz, Julio
AU  - Arcos Castellanos, Lucía
AU  - Ruiz-Ojeda, Francisco Javier
AU  - Brandimonte-Hernández, Marco
AU  - Feliú-Batlle, Jaime
AU  - Hummel, Thomas
AU  - Palma Milla, Samara
AU  - Gil, Ángel
TI  - The Regular Consumption of a Food Supplement Containing Miraculin Can Contribute to Reducing Biomarkers of Inflammation and Cachexia in Malnourished Patients with Cancer and Taste Disorders: The CLINMIR Pilot Study
AID  - 10.1101/2024.06.23.24309349
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.23.24309349
4099  - http://medrxiv.org/content/early/2024/06/24/2024.06.23.24309349.short
4100  - http://medrxiv.org/content/early/2024/06/24/2024.06.23.24309349.full
AB  - Background Taste disorders are common in patients with cancer undergoing systemic therapy, persist during treatment and are associated with reduced food intake, increasing the risk of malnutrition. Cachectic syndrome, which is common in these patients and characterized by marked weight loss, anorexia, asthenia and anemia, is linked to the presence and growth of the tumor and leads to systemic inflammation. Synsepalum dulcificum is a plant whose berries contain miraculin, a glycoprotein that transforms sour tastes into sweet ones and could serve to ameliorate taste disorders in patients with cancer.Objective To evaluate the effect of the regular intake of Dried Miracle Berries (DMB), a novel food containing miraculin, on several biomarkers of inflammation and cachexia in malnourished patients with cancer and taste disorders receiving systemic antineoplastic therapy.Materials and methods Triple-blind, randomized, placebo-controlled clinical trial. Thirty-one patients with cancer of various etiologies receiving chemotherapy were enrolled in a pilot study and divided into three groups. The first group received a tablet containing 150 mg of DMB (standard dose); the high-dose group received a tablet of 300 mg of DMB, and the third group received a tablet with 300 mg of the placebo for three months before each main meal. Plasma levels of several molecules associated with inflammation and cancer cachexia were measured using the X-MAP Luminex multiplexing platform.Results The three groups showed a decrease in the plasma levels of IL-6, IL-1β, TNF-α, and PIF throughout the intervention, although the percentage change from baseline was greater in patients receiving a standard dose of DMB. In contrast, the CNTF concentration only decreased in the DMB standard-dose group. This group also presented the greatest reduction in the IL-6/ IL-10 ratio, while IL-15 and IL-10 increased in the groups treated with DMB but not in the placebo. Regardless of DMB consumption, sTNFR-II tended to decrease with treatment in patients who responsed well to the antineoplastic treatment. We did not find significant correlations between cytokines and sensory variables or dietary and nutritional status.Conclusions The regular consumption of a standard dose of the food supplement DMB containing miraculin along with a systemic antineoplastic treatment can contribute to reducing biomarkers of inflammation and cachexia in malnourished patients with cancer exhibiting taste disorders.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05486260Clinical Protocols https://www.mdpi.com/2072-6643/15/21/4639 Funding StatementThis study is funded by Medicinal Gardens S.L. through the Center for the Development of Industrial Technology and Innovation (CDTI), Cervera Transfer R&D Projects. Ref. IDI-20210622. (Ministry of Science, Innovation and Universities, Spain).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted following the Declaration of Helsinki and approved by the Ethics Committee of Hospital Universitario La Paz (protocol code 6164 and Jun 23rd, 2022 date of approval). Informed consent was obtained from all subjects involved in the study. Clinical Trial NCT05486260 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors